Supplementary Materials

Supplementary Material for:

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates

Gurunadh R. Chichili, Ling Huang, Hua Li, Steve Burke, Leilei He, Qin Tang, Linda Jin, Sergey Gorlatov, Valentina Ciccarone, Francine Chen, Scott Koenig, Michele Shannon, Ralph Alderson, Paul A. Moore, Syd Johnson, Ezio Bonvini*

*Corresponding author. E-mail: bonvinie{at}

Published 27 May 2015, Sci. Transl. Med. 7, 289ra82 (2015)
DOI: 10.1126/scitranslmed.aaa5693

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Physicochemical characterization of MGD006.
  • Fig. S2. MGD006 activity in primary AML patient PBMCs.
  • Fig. S3. MGD006 activity in a primary AML patient bone marrow specimen.
  • Fig. S4. MGD006-mediated redirected killing of KG-1a cells ex vivo.
  • Fig. S5. Pharmacokinetics of MGD006 in cynomolgus monkeys.
  • Fig. S6. PDCs in MGD006-treated monkeys.
  • Fig. S7. Determination of ADA reactivity to MGD006 components.
  • Fig. S8. Effects of MGD006 treatment on circulating T cell activation markers and subtypes in cynomolgus monkeys (group 2 to 4 data).
  • Fig. S9. PD-L1 expression on KG-1a and Kasumi-3 cells.
  • Fig. S10. MGD006-induced cytokine production in cynomolgus monkeys.
  • Fig. S11. Effects of MGD006 treatment on RBCs and reticulocytes in cynomolgus monkeys.
  • Fig. S12. Effect of MGD006 on bone marrow progenitors.
  • Table S1. Myeloid/erythroid ratio in smears of bone marrow aspirates from monkeys treated with MGD006.
  • Table S2. P values comparing tumor volumes in mice treated with MGD006 or control DART.
  • Table S3. P values comparing CD123+ cells in bone marrow samples from cynomolgus monkeys treated with MGD006 or vehicle.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S4 (Microsoft Excel format). Individual data for in vivo experiments (provided as a separate Excel file).

[Download Table S4]